Skip to content

2030 at other companies

AvePoint, Inc. logo
AvePoint, Inc.AVPT
2.9M
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$32.3M+669%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$37.56M-0.6%
NextNRG, Inc. Common Stock logo
NextNRG, Inc. Common StockNXXT
13K
PJT Partners logo
PJT PartnersPJT
5.8M-19.3%
EVI Industries logo
EVI IndustriesEVI
85.7K-33.6%

Other financials

Income statement

See full
Revenue$18.7M+322%
Operating income$3.9M+141%
Net income$19.9M+331%
EPS (diluted)-$0.49+26.5%

Balance sheet

See full
Cash & equivalents$7.9M+87.3%
Total debt$100.3M-16.6%
Total equity-$128.6M-1,002%
Total assets$337.9M-15.5%

Cash flow

See full
Operating cash flow-$9.4M+6.3%
CapEx$96.0K-85.5%
Free cash flow-$9.4M+6.7%

Valuation

See full
Market cap$52.86M+2,018%
Enterprise value$145.33M+40.6%

Profitability

See full
Operating margin548.5%-323pp
Net margin517.9%-235pp
FCF margin156.8%-40.4pp

Returns & leverage

See full
Return on equity-1,647.1%-2,080pp
Debt / equity8.4×-23.8×

Where this comes from

Reported directly by Beneficient in its filing.

Tagged under the XBRL concept ben:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmountYearFive.

The official record: Beneficient’s 10-K, filed September 29, 2025, on SEC EDGAR. View the filing →

Ask your AI about Beneficient's 2030.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beneficient's 2030?
Beneficient (BENF) reported 2030 of $0 in Q1 2025.
What does 2030 mean?
Represents the total value or count of equity-based awards granted to employees or directors that have not yet met the necessary service or performance vesting conditions. This metric reflects future compensation obligations and potential dilution for existing shareholders. It serves as a key indicator of long-term incentive alignment and human capital retention strategies.